IP Library › Granted Patent US 12,543,713
Granted Patent B2
US 12,543,713 · App. 17/550,927 · Granted Feb 10, 2026

Mice that make heavy chain antibodies

Inventors: Lynn Macdonald (Harrison, NY); Sean Stevens (Del Mar, CA); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278A01K67/0275A01K67/0276C07K16/00C07K16/462C12N15/8509A01K2217/072A01K2217/075A01K2227/105A01K2267/01C07K2317/14C07K2317/20C07K2317/21C07K2317/50C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,543,713
App. No.
17/550,927
Granted
Feb 10, 2026
Kind
B2
Abstract

Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.

Claims (59)

1 . A method of providing a rodent that expresses IgG heavy chain antibodies lacking a C H 1 domain and also expresses IgM antibodies comprised of two light chains and two heavy chains, which IgM heavy chains each include a functional C H 1 domain, the method comprising:

(i) genetically modifying a rodent embryonic stem(ES) cell such that it comprises, at an endogenous Ig heavy chain constant region,

(a) an endogenous IgM constant region gene that encodes an endogenous IgM isotype comprising a C H 1 domain, and

(b) a replacement of an endogenous IgG constant region gene with a genetically modified rodent IgG constant region gene,

wherein the endogenous IgG constant region gene and the genetically modified rodent IgG constant region gene encode the same isotype, and

wherein the genetically modified rodent IgG constant region gene comprises:

a nucleotide sequence comprising from 5′ to 3′: an endogenous switch region, a splice acceptor, a C H 2 exon, a C H 2 intron, and a C H 3 exon, and

deletion in a sequence encoding a C H 1 domain, and encodes a rodent IgG isotype devoid of a C H 1 domain and

(ii) generating a genetically modified rodent from the genetically modified rodent ES cell,

wherein the generated rodent expresses

(a) an IgM immunoglobulin heavy chain that comprises an Ig heavy chain variable domain operably linked to the endogenous IgM isotype comprising a C H 1 domain, and

(b) an IgG immunoglobulin heavy chain that consists essentially of, from N-terminal to C-terminal, an Ig heavy chain variable domain operably linked to the rodent IgG isotype devoid of a C H 1 domain, and

wherein the rodent is a rat or a mouse.

2 . The method of claim 1 , wherein the rodent ES cell further comprises unrearranged human Ig heavy chain variable region VH, DH, and JH gene segments operably linked to the endogenous Ig heavy chain constant region such that the rodent expresses:

(a) a chimeric human/rodent IgM immunoglobulin heavy chain that comprises a human Ig heavy chain variable domain operably linked to the endogenous IgM isotype comprising a C H 1 domain and

(b) a chimeric human/rodent IgG immunoglobulin heavy chain that consists essentially of, from N-terminal to C-terminal, a human Ig heavy chain variable domain operably linked to the rodent IgG isotype devoid of a C H 1 domain.

3 . The method of claim 2 , wherein the unrearranged human Ig heavy chain variable region V H , D H , and J H gene segments replace one or more endogenous Ig heavy chain variable region gene segments.

4 . The method of claim 1 , wherein the genetically modified rodent IgG constant region gene further comprises a deletion in a sequence encoding a hinge such that the rodent IgG isotype is devoid of a C H 1 domain and a hinge.

5 . The method of claim 1 , wherein the endogenous IgG constant region gene is selected from the group consisting of

(i) an IgG1 constant region gene,

(ii) an IgG2a constant region gene,

(iii) an IgG2b constant region gene,

(iv) an IgG3 constant region gene, and

(v) combinations thereof.

6 . The method of claim 5 , wherein the endogenous IgG constant region gene is an IgG1 constant region gene and/or an IgG3 constant region gene.

7 . The method of claim 6 , wherein the endogenous IgG constant region gene is an IgG1 constant region gene, and wherein the rodent expresses:

(a) an endogenous IgG3 constant region gene comprising an IgG3 C H 1 gene segment, an IgG3 hinge region, an IgG3 C H 2 gene segment, and an IgG3 C H 3 gene segment;

(b) an endogenous IgG2a constant region gene comprising an IgG2a C H 1 gene segment, an IgG2a hinge region, an IgG2a C H 2 gene segment, and an IgG2a C H 3 gene segment; and

(c) an endogenous IgG2b constant region gene comprising an IgG2b C H 1 gene segment, an IgG2b hinge region, an IgG2b C H 2 gene segment, and an IgG2b C H 3 gene segment.

8 . The method of claim 7 , further characterized in that the rodent additionally expresses:

(d) an endogenous IgM constant region gene comprising an IgM C H 1 gene segment, an IgM C H 2 gene segment, and an IgM C H 3 gene segment;

(e) an endogenous IgD constant region gene comprising an IgD C H 1 gene segment, an IgD hinge region, an IgD C H 2 gene segment, and an IgD C H 3 gene segment;

(f) an endogenous IgA constant region gene comprising an IgA C H 1 gene segment, an IgA hinge region, an IgA C H 2 gene segment, and an IgA C H 3 gene segment; and

(g) an endogenous IgE constant region gene comprising an IgE C H 1 gene segment, an IgE C H 2 gene segment, and an IgE C H 3 gene segment.

9 . The method of claim 7 , wherein the genetically modified rodent IgG constant region gene comprises, at the deletion point, a sequence set forth as SEQ ID NO:17.

10 . The method of claim 5 , wherein the endogenous IgG constant region gene is an IgG1 constant region gene and an endogenous IgG2a constant region gene, and

wherein the endogenous Ig heavy chain constant region further comprises:

(i) a deletion of an endogenous IgD constant region gene;

(ii) a deletion of an endogenous IgG3 constant region gene;

(iii) a deletion of an endogenous IgG2b constant region gene;

(iv) a deletion of an endogenous IgE constant region gene; or

(v) a deletion of an endogenous IgA constant region gene.

11 . The method of claim 5 , wherein the endogenous IgG constant region gene is an IgG1 constant region gene, and wherein the endogenous Ig heavy chain constant region further comprises:

(i) a deletion of an endogenous IgD constant region gene;

(ii) a deletion of an endogenous IgG3 constant region gene;

(iii) a deletion of an endogenous IgG2a constant region gene;

(iv) a deletion of an endogenous IgG2b constant region gene;

(v) a deletion of an endogenous IgE constant region gene; or

(vi) a deletion of an endogenous IgA constant region gene.

12 . The method of claim 1 , wherein the rodent expresses the IgM immunoglobulin heavy chain associated with a cognate light chain.

13 . The method of claim 1 , wherein the rodent ES cell is from a mouse strain selected from the group consisting of a 129 strain, a C57BL/6 strain, and a mixed 129×C57BL/6 strain.

14 . The method of claim 13 , wherein the rodent ES cell is 50% 129 and 50% C57BL/6.

15 . A method for isolating an Ig heavy chain variable domain and/or nucleic acid encoding same comprising:

isolating a lymphocyte, or hybridoma produced therefrom, from a rodent made according to the method of claim 1 , wherein the lymphocyte or hybridoma expresses a rearranged Ig heavy chain variable region encoding an Ig heavy chain variable domain of an antibody that specifically binds an antigen.

16 . The method of claim 15 , wherein the Ig heavy chain variable domain is a human Ig heavy chain variable domain that is encoded by a rearranged human Ig heavy chain variable region.

17 . The method of claim 16 , further comprising isolating the rearranged human Ig heavy chain variable region from the isolated lymphocyte, or a hybridoma produced therefrom.

18 . The method of claim 17 , further comprising expressing the rearranged human Ig heavy chain variable region in a host cell.

19 . The method of claim 18 , wherein the rearranged human Ig heavy chain variable region is operably linked to a human Ig heavy chain constant region gene.

20 . The method of claim 18 , wherein the human Ig heavy chain constant region gene comprises a deletion in a sequence encoding a C H 1 domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2025
From: MACDONALD, LYNN; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 071616/0739 →
Continuity (5)
Continuation 14674198 · Mar 31, 2015
Continuation 14267279 · May 1, 2014
Division 12965050 · Dec 10, 2010
Provisional Application 61285250 · Dec 10, 2009
Related Publication 20220201993A1 · Jun 30, 2022
References Cited (219)
US 5759808A · Casterman · 1998 [cited by applicant]
US 5800988A · Casterman · 1998 [cited by applicant]
US 5840526A · Casterman · 1998 [cited by applicant]
US 5874541A · Casterman · 1999 [cited by applicant]
US 6005079A · Casterman · 1999 [cited by applicant]
US 6015695A · Casterman · 2000 [cited by applicant]
US 6080910A · Schreiber et al. · 2000 [cited by applicant]
US 6596541B2 · Murphy et al. · 2003 [cited by applicant]
US 6765087B1 · Casterman · 2004 [cited by applicant]
US 6838254B1 · Hamers · 2005 [cited by applicant]
US 7241733B2 · Heavner · 2007 [cited by applicant]
US 7541513B2 · Bruggermann · 2009 [cited by applicant]
US 7582298B2 · Stevens · 2009 [cited by applicant]
US 7722871B2 · Casterman · 2010 [cited by applicant]
US 7786047B2 · Casterman · 2010 [cited by applicant]
US 7790367B2 · Casterman · 2010 [cited by applicant]
US 7794981B2 · Hamers · 2010 [cited by applicant]
US 8293500B2 · Wiley et al. · 2012 [cited by applicant]
US 20030118592A1 · Ledbetter · 2003 [cited by applicant]
US 20040137570A1 · Grosveld · 2004 [cited by applicant]
US 20040142432A1 · Grosveld · 2004 [cited by applicant]
US 20060015949A1 · Lonberg · 2006 [cited by applicant]
US 20070280945A1 · Stevens · 2007 [cited by applicant]
US 20080196112A1 · Romagne · 2008 [cited by applicant]
US 20090042254A1 · Retallack · 2009 [cited by applicant]
US 20090098134A1 · Buelow · 2009 [cited by applicant]
US 20090271880A1 · Grosveld · 2009 [cited by applicant]
US 20090285805A1 · Grosveld · 2009 [cited by applicant]
US 20090307787A1 · Grosveld · 2009 [cited by applicant]
US 20100122358A1 · Bruggermann · 2010 [cited by applicant]
US 20100197897A1 · Grosveld · 2010 [cited by applicant]
US 20100216974A1 · Grosveld · 2010 [cited by applicant]
US 20110004948A1 · Grosveld · 2011 [cited by applicant]
US 20110004949A1 · Grosveld · 2011 [cited by applicant]
WO 1989007142A1 · 1989 [cited by applicant]
WO 1994004690A1 · 1994 [cited by applicant]
WO 1998024893A2 · 1998 [cited by applicant]
WO 2002012437A2 · 2002 [cited by applicant]
WO 2002085944A2 · 2002 [cited by applicant]
WO 2002085945A2 · 2002 [cited by applicant]
WO 2003002609A2 · 2003 [cited by applicant]
WO 2003035694A2 · 2003 [cited by applicant]
WO 2004003019A2 · 2004 [cited by applicant]
WO 2004049794A2 · 2004 [cited by applicant]
WO 2004058820A2 · 2004 [cited by applicant]
WO 2005005638A2 · 2005 [cited by applicant]
WO 2008035216A2 · 2005 [cited by applicant]
WO 2005070966A2 · 2005 [cited by applicant]
WO 2006008548A2 · 2006 [cited by applicant]
WO 2007059782A1 · 2007 [cited by applicant]
WO 2008122886A2 · 2008 [cited by applicant]
WO 2008151081A1 · 2008 [cited by applicant]
WO 2009013620A2 · 2009 [cited by applicant]
WO 2009030237A2 · 2009 [cited by applicant]
WO 2010109165A2 · 2010 [cited by applicant]
Alexander et al. (1982) “γ heavy chain disease in man: cDNA sequence supports partial gene deletion model,” Proc. Natl. Acad. Sci. USA, 79:3260-3264. [cited by applicant]
Alt et al. (1982) “Joining of immunoglobulin heavy chain gene segments: Implications from a chromosome with evidence of three D-J [cited by applicant]
Anderson et al. (2007) “New markers for murine memory B cells that define mutated and unmutated subsets,” JEM, 204(9):2103-2114. [cited by applicant]
Azwai et al. (1996) “Immunonoglobulins of Camel ( [cited by applicant]
Babcook et al. (1996) “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificites,” Proc. Natl. Acad. Sci. USA, 93:7843-7848. [cited by applicant]
Barthelemy et al. (2008) “Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains,” J. Bio. Chem., 283(6):3639-3654. [cited by applicant]
Berman et al (1988) “Content and organization of the human Ig V [cited by applicant]
Boder and Wittrup (1997) “Yeast surface display for screening combinatorial polypeptide libraries,” Nature Biotechnology, 15:553-557. [cited by applicant]
Bond et al. (2005) “A Structure-Based Database of Antibody Variable Domain Diversity,” J. Mol. Biol. 348:699-709. [cited by applicant]
Brandt et al. (1984) “Loss of a Consensus Splice Signal in a Mutant Immunoglobulin Gene Eliminates the CH [cited by applicant]
Brandtzaeg et al. (2004) “Characteristics of Mucosal B Cells with Emphasis on the Human Secretory Immune System,” Chapter 15, Molecular Biology of B Cells, 223-246, 13 pages. [cited by applicant]
Brezinschek, et al., “Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction,” J. Immunol., 1995, 155:190-202. [cited by applicant]
Brüggemann (2001) “Human Antibody Expression in Transgenic Mice,” Archivum Immunologiae et Therapiae Experimantalis, 49:203-208. [cited by applicant]
Brüggemann et al. (2006) “Heavy-Chain-Only Antibody Expression and B-Cell Development in the Mouse,” Crit. Rev. Immunol., 26(5):377-390. [cited by applicant]
Cai and Garen (1996) “A melanoma-specific V [cited by applicant]
Cai and Garen (1997) “Comparison of fusion phage libraries displaying V [cited by applicant]
Chothia (1985) “Domain Association in Immunoglobulin Molecules The Packing of Variable Domains,” J. Mol. Biol., 186:651-663. [cited by applicant]
Coloma and Morrison (1997) “Design and production of novel tetravalent bispecific antibodies,” Nature Biotechnology, 15:159-163. [cited by applicant]
Conrath et al. (2001) “β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae,” Antimicrob. Agents Chemother., 45(10):2807-2812. [cited by applicant]
Conrath et al. (2001) “Camel Single-domain Antibodies a Modular Building Units in Bispecific and Bivalent Antibody Constructs,” Journal of Biological Chemistry, 276(10):7346-7350. [cited by applicant]
Coronella et al. (2000) “Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells,” Nucleic Acids Research, 28(20):e85, 7 pages. [cited by applicant]
Dalton (2009) “When a Llama Is Laid Back, It's Not the Only Beneficiary,” The Wall Street Journal, published online at http://www.wsj.com, 3 pages. [cited by applicant]
Davies et al. (1996) “Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability,” Protein Eng., 9(6):531-537. [cited by applicant]
Davies and Riechmann (1994) “‘Camelising’ human antibody fragments: NMR studies on VH domains,” FEBS Letters 339:285-290. [cited by applicant]
Davies and Riechmann (1995) “Antibody VH Domains as Small Recognition Units,” Nature Biotechnology, 13:475-479. [cited by applicant]
Davies and Reichmann (1996) “Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability,” Protein Engineering, 9:531-537. [cited by applicant]
Decanniere et al. (1999) “A single-domain antibody fragment in complex with Rnase A: non-canonical loop structions and nonomolar affinity using two CDR loops,” Structure, 7(4):361-370. [cited by applicant]
De Haard et al. (2005) “Llama Antibodies against a Laclococcal Protein Located at the Tip of the Phage Tail Prevent Phage Infecton,” J. Bacteriol., 187(13):4531-4541. [cited by applicant]
Dennis (2002) “Welfare issues of genetically modified animals,” ILAR Journal, 43(2):100-109. [cited by applicant]
Desmyter et al. (1996) “Crystal structure of a camel single-domain V [cited by applicant]
De Wildt, et al., “Analysis of Heavy and Light Chain Pairings Indicates that Receptor Editing Shapes the Human Antibody Repertoire,” J. Mol. Biol., 1999, 285:895-901. [cited by applicant]
Dörner and Radbruch (2007) Antibodies and B Cell Memory in Viral Immunity, Immunity 27:384-392. [cited by applicant]
Dudgeon et al. (2012) “General strategy for the generation of human antibody variable domains with increased aggregation resistance,” PNAS, 10879-10884. [cited by applicant]
Dumoulin et al. (2002) “Single-domain antibody fragments with high conformational stability,” Protein Sci., 11:500-515. [cited by applicant]
Echelard (2009) “Year of the ox,” Nature Biotechnology, 27(2):146-147. [cited by applicant]
Ehlich et al. (1993) “Immunoglobulin Heavy and Light Chain Genes Rearrange Independently at Early Stages of B Cell Development,” Cell, 72:695-704. [cited by applicant]
Ewert et al. (2002) “Biophysical Properties of Camelid VHH Domains Compared to Those of Human VH3 Domains,” Biochem., 41:3628-3636. [cited by applicant]
Foster et al., “Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM B Cells,” J. Clin. Invest., 99(7):1614-1627. [cited by applicant]
Galler et al. (2004) “Surface μ Heavy Chain Signals Down-Regulation of the V(D)J-Recombinase Machinery in the Absence of Surrogate Light Chain Components,” J. Exp. Med., 199(11):1523-1532. [cited by applicant]
Geraldes et al. (2007) “Ig heavy chain promotes mature β cell survival in the absence of light chain,” J. Immunol., 179:1659-1668. [cited by applicant]
Ghahroudi et al. (1997) “Selection and identification of single domain antibody fragments from camel heavy chain antibodies,” FEBS Letters, 414:521-526. [cited by applicant]
Giersberg et al. (2010) “Covalent dimerization of camelidae anti-human TNF-alpha single domain antibodies by the constant kappa light chain domain improves neutralizing activity,” Biotech and Bioeng., 106(1):161-166, (s… [cited by applicant]
Green et al. (1994) “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,” Nature Genetics, 7:13-21. [cited by applicant]
Green (1999) “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,” J. Immunol. Methods, 231:11-23. [cited by applicant]
Hamers-Casterman et al. (1993) “Naturally occuring antibodies devoid of light chains,” Nature, 363:446-448. [cited by applicant]
Harmsen et al. (2000) “Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features,” Mol. Immunol., 37:579-590. [cited by applicant]
Harmsen et al (2007) “Properties, production, and applications of camelid single-domain antibody fragments,” Appl. Microbiol. Biotech., 77:13-22. [cited by applicant]
Hasan et al. (2002) “Incomplete block of B cell development and immunoglobulin production in mice carring the μMT mutation on the BALB/c background,” Eur. J. Immunol., 32:3463-3471. [cited by applicant]
Hendershot et al. (1987) “Assembly and secretion of heavy-chains that do not associate post translationally with immunoglobulin heavy-chain binding-protein,” J. Cell Biol., 104(3):761-767. [cited by applicant]
Holt, et al. (2003) “Domain antibodies: proteins for therapy,” Trends in Biotech., 21(11):484-490. [cited by applicant]
Hoogenboom (2005) “Selecting and screening recombinant antibody libraries,” Nature Biotechnology, 23(9):1105-1116. [cited by applicant]
Janeway et al. (1999) “The Development of B Lymphocytes,” Chapter 6, Immuno Biology The Immune System in Health and Disease, Fourth Edition, Current Biology Publications, USA, 34 pages. [cited by applicant]
Janeway and Travers (2008) Immunobiology: The Immune System in Health and Disease, 1st Edition, Current Biology, pp. 8:10-8:19. [cited by applicant]
Janssens et al. (2006) “Generation of heavy-chain-only antibodies in mice,” PNAS, 103 (41 ):15130-15135; including 7 additional pages of supporting information (Figures 7, 8, 9 and Supporting Methods). [cited by applicant]
JAX Mice Database, Printout from http://jaxmice.jax.org/strain/002288.html, printed Aug. 23, 2013, pp. 1-2. [cited by applicant]
Jendreyko et al. (2003) “Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface Receptors,” Journal of Biological Chemistry, 278(48):47812-47819. [cited by applicant]
Kellermann and Green (2002) “Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics,” Current Opinion in Biotechnology, 13:593-597. [cited by applicant]
Kitamura et al. (1991) “A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene,” Nature, 350:423-426. [cited by applicant]
Kitamura and Rajewsky (1992) “Targeted disruption μ chain membrane exon causes loss of heavy-chain allelic exclusion,” Nature, 356:154-156. [cited by applicant]
Kodituwakku et al. (2003) “Isolation of antigen-specific B cells,” Immunology and Cell Biology, 81:163-170. [cited by applicant]
Kuroiwa et al. (2002) “Cloned transchromosomic calves producing human immunoglobulin,” Nature Biotechnology, 20:889-894. [cited by applicant]
Lanzavecchia et al. (2007) “Human monoclonal antibodies by immortalization of memory B cells,” Current Opinion in Biotechnology, 18:523-528. [cited by applicant]
Lee et al. (1999) “BiP and Immunoglobulin Light Chain Cooperate to Control the Folding of Heavy Chain and Ensure the Fidelity of Immnoglobulin Assembly,” Molecular Biology of the Cell, 10:2209-2219. [cited by applicant]
Le Franc (2000) Current Protocols in Immunology Appendix, 1P:1-37. [cited by applicant]
Liao et al., (2009) “High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies,” Journal of Virological Methods, 158:171-179. [cited by applicant]
Liu (2009) “Isolation and characterization of human anti-VEGF (165) monoclonal antibody with anti-tumor efficacy from transgenic mice expressing human immunoglobulin loci,” Cancer Letters, 273(1):28-34. [cited by applicant]
Lonberg et al. (1994) “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, 368:856-859. [cited by applicant]
Lonberg (2005) “Human antibodies from transgenic animals,” Nature Biotechnology, 23(9):1117-1125. [cited by applicant]
Macdonald et al. (2006) “Velocigene Technology Extended to Humanization of Several Megabases of complex Gene Loci,” First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2006… [cited by applicant]
Macpherson and Lamarre (2002) “BLySsful Interactions between DCs and B cells,” Nature Immunology, 3(9):798-800. [cited by applicant]
Manz et al., (2005) “Maintenance of Serum Antibody Levels,” Annu. Rev. Immunol., 23:367-386. [cited by applicant]
Masuda et al. (2006) “The role of interface framework residues in determining antibody V [cited by applicant]
Matheson et al. (2009) “Light chain-deficient mice produce novel multimeric heavy-chain-only IgA by faulty class switching.” Int. Immunol., 21(8):957-966. [cited by applicant]
Mcheyzer-Williams and Ahmed (1999) “B cell memory and the long-lived plasma cell,” Current Opinion in Immunology, 11:172-179. [cited by applicant]
Minges Wols (2005) “Plasma Cells,” Wiley Online Library, pp. 1-8, doi:10.1038/npg.els.0004030. [cited by applicant]
Molecular Biology of B Cells, 1st Edition, Academic Press, Feb. 18, 2003, Edited by Tasuku Honjo, Michael Reth, Andreas Radbruch, Frederick Alt, Tasuku Honjo, Michael Neuberger, United States of America, ISBN: 978-0-12-… [cited by applicant]
Moran (2013) “Mouse platforms jostle for slice of humanized antibody market,” Nature Biotech. (4):267-268. [cited by applicant]
Murphy et al. (2008) Janeway's Immunobiology 7th Edition. New York: Garland Science, Printed in USA., Chapters 9 and 10, pp. 386-446. [cited by applicant]
Muyldermans et al. (1994) “Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains,” Protein Engineering, 7(9):1129-1135. [cited by applicant]
Muyldermans and Lauwereys (1999) “Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies,” Journal of Molecular Recognition, 12:131-140. [cited by applicant]
Muyldermans (2001) “Single domain camel antibodies: current status,” Rev. Mol. Biotech., 74:277-302. [cited by applicant]
Muyldermans (2001) “Recognition of antigens by single-domain antibody fragments: the superflous luxury of paired domains,” Trends in Biochem. Sci., 26(4):230-235. [cited by applicant]
Muyldermans et al. (2003) “Camel antibodies and single-domain antibodies,” published online at http://ultr.vub.ac.be/ULTR/camel_antibodies.html, 2 pages. [cited by applicant]
Nguyen et al. (1999) “Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of the functional camel IgG2A heavy-chain antibodies,” Mol. Immunol., 36:515-524. [cited by applicant]
Nguyen et al. (2003) “Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells,” Immunol., 109:93-101. [cited by applicant]
Nicholson et al. (1999) “Antibody Repertoires of Four-and Five-Feature Translocus Mice Carrying Human Immunoglobulin Heavy Chain and κ and λ Light Chain Yeast Artificial Chromosomes,” Journal of Immunology, 163:6898-690… [cited by applicant]
Nieba et al. “Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment,” Protein Eng., 10(4):435-444. [cited by applicant]
Nitschke and Fearon (2003) “Regulation of Antigen Receptor Signaling by the Co-Receptors, CD19 and CD22,” Chapter 12, Molecular Biology of B Cells, 171-186, 9 pages. [cited by applicant]
Omidfar et al. (2004) “Production of a Novel Camel Single-Domain Antibody Specific for the Type III Mutant EGFR,” Tumor Biol. 25:296-305. [cited by applicant]
Omidfar et al. (2004) “Production and Characterization of a New Antibody Specific for the Mutant EGR Receptor, EGFRvIII, in Camelus bactrianus,” Tumor Biol., 25:179-187. [cited by applicant]
Orinska et al. (2002) “Novel B cell population producing functional IgG in the absence of membrane IgM expression,” Eur. J. Immunol., 32:3472-3480. [cited by applicant]
Padlan et al. (1986) “Antibody Fab Assembly: the Interface Residues Between CH1 and CL,” Molecular Immunology, 23(9):951-960. [cited by applicant]
Pasqualini and Arap (2004) “Hybridoma-free generation of monoclonal antibodies,” PNAS, 101(1):257-259. [cited by applicant]
Paul (1993/2003/2008) Fundamental Immunology, 6th ed., Lippincott Williams &Wilkins, a Wolters Kluwer business, Philadelphia PA USA, 12 pages. [cited by applicant]
Radbruch et al. (2006) “Competence and competition: the challenge of becoming a long-lived plasma cell,” Immunology, 6:741-750. [cited by applicant]
Reiter et al. (1999) “An Antibody Single-domain Phage Display Library of a Native Heavy Chain Variable Region: Isolation of Functional Single-domain VH Molecules with a Unique Interface,” J. Mol. Biol., 290:685-698. [cited by applicant]
Ren et al. (2004) “Silencing of the immunoglobulin heavy chain locus by removal of all eight constant-region genes in a 200-kb region,” Genomics, 84:686-695. [cited by applicant]
Riechmann (1996) “Rearrangement of the Former VL Interface in the Solution Structure of a Camelised, Single Antibody VH Domain,” J. Mol. Biol., 259:957-969. [cited by applicant]
Riechmann et al. (1999) “Single domain antibodies: comparison of camel VH and camelised human VH domains,” J. Immunol. Methods, 231:25-38. [cited by applicant]
Ronai et al. (2003) “Use of a simple, general targeting vector for replacing the DNA of the heavy chain constant region in mouse hybridoma cells,” J. Immunol. Methods, 275:191-202. [cited by applicant]
Rouet et al. (2015) “Fully Human V [cited by applicant]
Sanderson et al. (1989) “B lymphocytes express and lose syndecan at specific stages of differentiation,” Cell Regulation, 1:27-35. [cited by applicant]
Scheid et al. (2009) “Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals,” Nature, 458:636-640. [cited by applicant]
Slifka et al., (1998) “Humoral Immunity Due to Long-Lived Plasma Cells,” Immunity, 8:363-372. [cited by applicant]
http://en.wikipedia.org/wiki/Somatic_hypermutation[May 10, 2016 2:27:30 PM]. [cited by applicant]
Stavnezer, J. et al., “Mechanism and Regulation of Class Switch Recombination,” Annu Rev. Immunol., 2008, 26:261-292. [cited by applicant]
Steinitz et al. (1997) “EB virus-induced B lymphocyte cell lines producing specific antibody,” Nature, 269:420-422. [cited by applicant]
Stevens et al. (2006) “Velocimmune: Humanization of Immunoglobulin Loc Using Velocigene Technology,” First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2016—Athens, Greece… [cited by applicant]
Tanaka et al. (2003) “Single Domain Intracellular Antibodies: A Minimal Fragment For Direct In Vivo Selection of Antigen-specific Intrabodies,” J. Mol. Biol., 331:1109-1120. [cited by applicant]
Tangye and Tarlinton (2009) “Memory B cells: Effectors of long-lived immune responses,” Eur. J. Immunol., 39:2065-2075. [cited by applicant]
Tanha et al. (2001) “Optimal Design Features of Camelized Human Single-domain Antibody Libraries,” Journal of Biological Chemistry, 276(27) 24774-24780. [cited by applicant]
Tanha et al. (2002) “Selection by phage display of llama conventional VH fragments withheavy chain antibody VHH properties,” Journal of Immunological Methods, 263:97-109. [cited by applicant]
Tarte et al., (2003) “Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation,” Blood, 102(2):592-600. [cited by applicant]
To et al. (2005) “Isolation of Monomeric Human V [cited by applicant]
Van Spriel et al. (2000) “Immunotherapeutic perspective for bispecific antibodies,” Immunology Today, 21(8):391-397. [cited by applicant]
Vu et al. (1997) “Comparison of llama VH sequences from conventional and heavy chain antibodies,” Molecular Immunology, 34(16-17):1121-1131. [cited by applicant]
Wang et al. (2009) “Conserved amino acid networks involved in antibody variable domain interactions,” Proteins, 76:99-114. [cited by applicant]
Ward et al. (0989) “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Wernery (2001) “Camelid Immunoglobulins and Their Importance for the New-Born—A Review,” J. Vet. Med, 48:560-568. [cited by applicant]
Wrammert et al., (2008) “Rapid cloning of high-affinity human monoclonal antibodies against influenza virus,” Nature, 667:672, doi:10.1038/nature06890. [cited by applicant]
Wu et al. (1993) “Length Distribution of CDRH3 in Antibodies,” Proteins: Structure, Function, and Genetics, 16:1-7. [cited by applicant]
Yefenof et al., (1985) “Preparation and analysis of antigen-specific memory B cells,” Journal of Immunology, 135:3777-3784. [cited by applicant]
Yoshiki and Moriwaki (2006) “Mouse Phenome Research, Implications of Genetic Background,” ILAR Journal, 47(2):94-102. [cited by applicant]
Zhou et al., (2009) “Developing tTA transgenic rats for inducible and reversible gene expression,” International Journal of Biological Sciences, 5:171-181. [cited by applicant]
Zou et al. (1994) “Cre-loxP-mediated gene replacement: a mouse strain producing humanized anitbodies,” Current Biology, 4(12):1099-1103. [cited by applicant]
Zou et al. (2001) “Truncation of the μ heavy chain alters BCR signalling and allows recruitment of CD5+ B cells,” International Immunology, 13(12):1489-1499. [cited by applicant]
Zou et al. (2005) “Expression of a Dromedary Heavy Chain-Only Antibody and B Cell Development in the Mouse,” J. Immunol., 175:3769-3779. [cited by applicant]
Zou et al. (2007) “Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice,” J. Exp. Med., 204(13):3271-3283, Supplemental Material (2 pages), Figure S1 and Table S1. [cited by applicant]
Zou et al. (2008) “Removal of the BiP-retention domain in Cμ permits surface deposition and developmental progression without L-chain,” Mol. Immunol., 45:3573-3579. [cited by applicant]
International Search Report for PCT/US2010/059845 and Written Opinion dated Mar. 17, 2011, 10 pages. [cited by applicant]
Declaration of Kerry Chester dated Oct. 16, 2016, 14 pages. [cited by applicant]
Declaration of Mike Clark dated May 20, 2015, 30 pages. [cited by applicant]
Declaration of Anne Corcoran dated May 15, 2017, 13 pages. [cited by applicant]
Declaration of Daniel Corcos dated May 20, 2015, 18 pages. [cited by applicant]
Declaration of Lutz Riechmann dated May 20, 2015, 40 pages. [cited by applicant]
Declaration of Peter Delves dated Oct. 18, 2016, 29 pages. [cited by applicant]
EESR with Respect to EP 15177538.4 Mailed Oct. 9, 2015. [cited by applicant]
EP1176383 Exhibit illustrating relevant stages in development with reference to documents cited in the opposition, 1 page. [cited by applicant]
EP1176383 Notice of Opposition to a European Patent May 19, 2015 by Regeneron Pharmaceuticals, Inc., 28 pages. [cited by applicant]
EP1176383 Notice of Opposition to a European Patent May 20, 2015 by Crescendo Biologics Limited, 56 pages. [cited by applicant]
EP1176383 Notice of Opposition to a European Patent May 20, 2015 by Ablynx, 24 pages. [cited by applicant]
EP1176383 Reply of Patent Proprietor to Notice of Opposition Nov. 3, 2015, 18 pages. [cited by applicant]
EP1176383 Annex to EPO Communication Opposition Jan. 5, 2016, 12 pages. [cited by applicant]
EP1176383 Letter Accompanying Submission in Opposition Proceedings by Proprietor Oct. 17, 2016, 4 pages. [cited by applicant]
EP1176383 Grounds for Decision Annex Opposition Dec. 22, 2016, 21 pages. [cited by applicant]
EP1176383 Statement of Grounds of Appeal on Behalf of Regeneron Apr. 28, 2017, 36 pages. [cited by applicant]
EP1176383 Annex to EPO Communication Opposition Dec. 22, 2016, 9 pages. [cited by applicant]
EP1864998 Notice of Opposition to a European Patent Jun. 23, 2014 by Regeneron Pharmaceuticals, Inc., 27 pages. [cited by applicant]
EP1864998 Reply of Patent Proprietor to Notice of Opposition Dec. 9, 2014, 18 pages. [cited by applicant]
EP1864998 Annex to EPO Communication Opposition Aug. 11, 2015, 3 pages. [cited by applicant]
EP1864998 Annex to EPO Communication Opposition Nov. 16, 2015, 3 pages. [cited by applicant]
EP1864998 Annex to EPO Communication Opposition Jun. 27, 2016, 3 pages. [cited by applicant]
EP1864998 Final Written Submissions Nov. 10, 2016, 14 pages. [cited by applicant]
EP1864998 Letter Regarding Opposition Proceedings by Proprietor Nov. 11, 2016, 2 pages. [cited by applicant]
EP1864998 Letter Regarding Opposition Proceedings by Proprietor Nov. 30, 2016, 2 pages. [cited by applicant]
EP1864998 Annex to EPO Communication Oral Proceedings Mar. 13, 2017, 6 pages. [cited by applicant]
EP1864998 Grounds for Decision Annex Opposition Mar. 13, 2017, 12 pages. [cited by applicant]
EP1864998 Interlocutory Decision in Opposition Proceedings Mar. 13, 2017, 2 pages. [cited by applicant]
EP1864998 EPO Communication Commencement of Proceedings Before the Board of Appeal May 30, 2017, 5 pages. [cited by applicant]
EP2411408 Notice of Opposition to a European Patent Aug. 25, 2016 by Ablynx, 25 pages. [cited by applicant]
EP2411408 Notice of Opposition to a European Patent Aug. 24, 2016 by Dr. Bernhard, 36 pages. [cited by applicant]
EP2411408 Notice of Opposition to a European Patent Aug. 23, 2016 by Regeneron, 37 pages. [cited by applicant]
EP2411408 Reply of Patent Proprietor to Notice of Opposition Feb. 17, 2017, 17 pages. [cited by applicant]
EP2411408 Submission in Opposition Proceedings Reply from Opponent Jun. 27, 2017, 5 pages. [cited by applicant]